Search Videos by Topic or Participant
Browse by Series:

Immunotherapy Combination Strategies in RCC

Discussant: Brian I. Rini, MD, Cleveland Clinic
Published: Sunday, Jan 25, 2015
For High-Definition, Click
Immunotherapy combination strategies in renal cell carcinoma could be hampered by toxicity concerns, believes Brian I. Rini, MD. The need for combination approaches with a PD-1 inhibitor and a CTLA-4 inhibitor should be personalized based on patient characteristics. However, deciding which patient should receive a combination versus a single-agent remains to be seen.
Slider Left
Slider Right
For High-Definition, Click
Immunotherapy combination strategies in renal cell carcinoma could be hampered by toxicity concerns, believes Brian I. Rini, MD. The need for combination approaches with a PD-1 inhibitor and a CTLA-4 inhibitor should be personalized based on patient characteristics. However, deciding which patient should receive a combination versus a single-agent remains to be seen.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x